Marketed in 48 countries across multiple continents, Zantac is a globally distributed brand of ranitidine hydrochloride, classified within the antiulcer and acid-related disorder category. For travellers and expatriates, it is one of the more recognisable names in the gastric-acid space, and the page reader is most often someone who has encountered it under prescription at home and is now trying to identify the same medication abroad — or, conversely, someone who has been handed an unfamiliar local brand and wants to know whether it is the equivalent of what they already know.
Ranitidine-containing products like Zantac are prescribed for a range of acid-related gastrointestinal conditions, including dyspepsia, gastro-oesophageal reflux, reflux oesophagitis, erosive oesophagitis, and the management of Zollinger-Ellison syndrome. The structured indication list further down this page reflects the registered uses across the markets in which Zantac is sold.
Because the brand has such a broad international footprint, travellers may run into Zantac itself in countries as different as Canada, Egypt, China, Belgium, and Chile. Regulatory status, packaging, and even prescription-versus-pharmacy classification can differ noticeably between these markets, and the availability of ranitidine specifically has been subject to regulatory review in several countries in recent years. A local pharmacist is in the best position to clarify what is currently on the shelf in any given country.
Other medications within the broader acid-related-disorders category — including different molecules entirely — are widely available worldwide under a range of brand names, and a pharmacist or physician familiar with the local formulary can identify what is appropriate. Decisions about starting, continuing, or substituting any acid-reducing therapy belong with a healthcare provider who knows the patient's history.
